Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Enjoy this offer
* See conditions under "Our services"

Valuation: Zai Lab Limited

Market Cap 1.94B 1.68B 1.55B 1.45B 2.72B 186B 2.77B 18.5B 7.16B 89.51B 7.28B 7.12B 311B P/E Ratio 2026 *
-7.97x
P/E Ratio 2027 * -9.46x
Enterprise Value 1.5B 1.3B 1.2B 1.12B 2.1B 143B 2.14B 14.28B 5.53B 69.05B 5.62B 5.5B 240B EV / Sales 2026 *
3.33x
EV / Sales 2027 * 2.61x
Free-Float
95.17%
Yield 2026 *
-
Yield 2027 * -
1 week+1.36%
Current month-1.32%
1 month-5.10%
3 months-10.24%
6 months-4.49%
Current year+0.68%
1 week 13.5
Extreme 13.5
15.2
1 month 13.5
Extreme 13.5
18.2
3 years 12.6
Extreme 12.6
38.2
5 years 12.6
Extreme 12.6
149
Manager TitleAgeSince
Chief Executive Officer 60 01/04/2014
Director of Finance/CFO 58 07/07/2023
President 62 01/12/2022
Director TitleAgeSince
Chairman 60 01/04/2014
Director/Board Member 82 01/01/2017
Director/Board Member 74 01/01/2017
Change 5-day change 1-year change 3-year change Capi.($)
+2.01%+1.36%-57.18%-42.69% 1.94B
+1.63%-1.21%+16.80%-18.09% 61.21B
+2.50%+7.58%+64.44%+216.37% 58.15B
-0.92%+28.60%+28.60%+28.60% 39.54B
+4.16%+16.25%-56.08%-64.88% 35.08B
+2.94%+2.04%+47.58%-35.26% 28.68B
+2.32%+10.05%+53.89%+76.65% 21.06B
+7.94%+1.18%+79.34%-59.73% 18.25B
-1.88%-5.07%-10.05%+93.76% 16.49B
+0.78%+0.78%+49.83%+98.01% 15.87B
Average +2.24%+1.25%+21.72%+29.27% 32.7B
Weighted average by Cap. +2.15%+1.44%+28.35%+43.41%

Financials

2026 *2027 *
Net sales 449M 389M 359M 336M 628M 42.96B 641M 4.28B 1.66B 20.71B 1.68B 1.65B 72.01B 596M 517M 476M 446M 834M 57.03B 851M 5.68B 2.2B 27.49B 2.24B 2.19B 95.58B
Net income -241M -209M -193M -181M -337M -23.07B -344M -2.3B -890M -11.12B -904M -885M -38.66B -156M -136M -125M -117M -219M -14.98B -224M -1.49B -578M -7.22B -587M -575M -25.11B
Net Debt -443M -385M -354M -332M -621M -42.43B -633M -4.23B -1.64B -20.45B -1.66B -1.63B -71.11B -387M -336M -310M -290M -542M -37.07B -554M -3.69B -1.43B -17.87B -1.45B -1.42B -62.14B
Logo Zai Lab Limited
Zai Lab Ltd is a holding company primarily engaged in biopharmaceutical business. The Company is focused on discovering, developing, and commercializing products that address medical conditions with significant unmet needs in the areas of oncology, immunology, neuroscience, and infectious disease. The Company has a series of patented drug candidates from the discovery stage to the late clinical project, including ZEJULA, OPTUNE, QINLOCK, NUZYRA and VYVGART, and others. The Company conducts its businesses within domestic and overseas markets.
Employees
-
Date Price Change
11/06/26 15.20 +2.01%
10/06/26 14.90 +3.47%
09/06/26 14.40 +0.70%
08/06/26 14.30 0.00%
05/06/26 14.30 -4.03%
Trader
Investor
-
Global
-
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
17.26USD
Average target price
33.30USD
Spread / Average Target
+92.95%

Quarterly revenue - Rate of surprise

40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!